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Abstract The purpose of the present work was to for-
mulate and evaluate cationic poly(lactic acid)-poly(ethyl-
ene glycol) (PLA-PEG) nanoparticles as novel non-viral
gene delivery nano-device. Cationic PLA-PEG nanoparti-
cles were prepared by nanoprecipitation method. The gene
loaded nanoparticles were obtained by incubating the
report gene pEGFP with cationic PLA-PEG nanoparticles.
The physicochemical properties (e.g., morphology, particle
size, surface charge, DNA binding efﬁciency) and biolog-
ical properties (e.g., integrity of the released DNA, pro-
tection from nuclease degradation, plasma stability, in vitro
cytotoxicity, and in vitro transfection ability in Hela cells)
of the gene loaded PLA-PEG nanoparticles were evaluated,
respectively. The obtained cationic PLA-PEG nanoparti-
cles and gene loaded nanoparticles were both spherical in
shape with average particle size of 89.7 and 128.9 nm,
polydispersity index of 0.185 and 0.161, zeta potentials of
?28.9 and ?16.8 mV, respectively. The obtained cationic
PLA-PEG nanoparticles with high binding efﬁciency
([95%) could protect the loaded DNA from the degrada-
tion by nuclease and plasma. The nanoparticles displayed
sustained-release properties in vitro and the released DNA
maintained its structural and functional integrity. It also
showed lower cytotoxicity than Lipofectamine 2000 and
could successfully transfect gene into Hela cells even in
presence of serum. It could be concluded that the estab-
lished gene loaded cationic PLA-PEG nanoparticles with
excellent properties were promising non-viral nano-device,
which had potential to make cancer gene therapy
achievable.
Keywords Cationic PLA-PEG nanoparticles
(DNA-PLA-PEG-NPs)   Gene therapy   Nanoprecipitation
method   Non-viral gene vector
Introduction
Gene therapy is a rapidly advancing ﬁeld with enormous
potential to treat vital human diseases such as cancer and
inheritedgeneticdisordersfundamentally.Thedevelopment
ofpotentgenetransfersystemsthatcandeliverforeigngenes
efﬁcientlyandsafelyintotargetcellsisofcrucialimportance
forsuccessfulgenetherapy.Thenon-viralvector,possessing
signiﬁcantly low safety risks and convenient preparation in
largequantitieseasilyandinexpensively,hasbeensuggested
as an alternative to viral vector [1]. Therefore, to develop a
safeandeffectivenonviralvectorsystemisanurgentmatter.
Among non-viral vectors, cationic gene delivery polymers
include poly(ethylenimine) (pEI), poly(2-dimethylamino-
ethyl methacrylate) (pDMAEMA), and poly-L-lysine (pLL)
have been frequently studied. Their gene binding and con-
densation capacities as well as their in vitro and in vivo
transfection properties have been reported in recently ample
literatures. These polymers are, however, non-degradable
andthereisconsequentlyariskthataccumulationinthebody
occurs, in particular after repeated administration. Further,
most of these cationic polymers show some cytotoxicity
likely due to adverse interactions with membranes resulting
in loss of cytoplasmic proteins, in permeabilization of cel-
lularmembranesandcollapseofthemembranepotential[2].
Consequently, there is a need for biodegradable gene
delivery polymers. It’s clear that the potential advantages of
biodegradable carriers are their reduced toxicity (provided
that degradation leads to non-toxic products) and avoidance
of accumulation of the polymer in the cells. Moreover, the
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plasmid DNA into the cytosol. Recently, the use of nano-
particles prepared with biocompatible and biodegradable
poly(D, L-lactide-co-glycolide)(PLGA)orpoly(D, L-lactide)
(PLA) polymers have attracted much attention due to their
favorablephysicochemicalcharacteristicsintermsofsafety,
stability,therelativeeaseoflarge-scaleproduction,andlack
of intrinsic immunogenicity that make them suitable candi-
dates for gene delivery application [3, 4]. These biodegrad-
able polymers undergo bulk hydrolysis thereby providing
sustained delivery of the therapeutic agent depending on the
polymer molecular weight and copolymer [5]. The degra-
dation products, lactic acid and glycolic acid, are removed
from the body through citric acid cycle. The degradation
time of PLGA/PLA can be altered from days to years by
varying the polymer molecular weight, the lactic acid to
glycolic acid ratio in copolymer. And recent studies dem-
onstrated rapid escape of PLGA nanoparticles from the
endo-lysosomal compartment into cytosol following their
uptake [6]. Therefore, PLGA/PLA nanoparticles might
be a promising and suitable candidate for gene delivery
application.
Although all features makes PLGA/PLA attractive to
many researchers involved in DNA delivery,it should be
noticed that simple PLGA/PLA nanoparticles shows,
indeed, several drawbacks as an ideal gene delivery system
[7]. First, because of the large size and hydrophilic char-
acter of DNA, encapsulation of plasmid DNA in hydro-
phobic PLGA/PLA nanoparticles is a challenge. Second,
the rate of DNA release from PLGA/PLA nanoparticles is
often too slow, and thus also subsequent antigen production
in case of DNA vaccination, which may prevent an optimal
immune response. Third, PLGA/PLA nanoparticles tend to
bind serum protein (such as albumin) in systemic appli-
cation due to the hydrophobic surface of PLGA/PLA
nanoparticles, which lead to opsonization and clearance by
the reticuloendothelial system (RES), limiting their thera-
peutic applications. Based on these considerations, it’s
necessary to modify the structure of PLGA/PLA in order to
improve its hydrophilicity, the gene loading efﬁciency,
release behavior, and stability both in vitro and in vivo.
Polyethylene glycol (PEG) is a commonly used modiﬁer,
which is expected to be a good candidate as the soluble
polymeric modiﬁer in organic synthesis or a pharmacologi-
cal polymer due to its high hydrophilicity, low cytotoxicity
and high cell permeability [8]. Reportedly, the PLA and
PLGA nanoparticles with either adsorbed or grafted PEG
layersexhibitprolongedbloodcirculationtimesandreduced
uptake by the reticuloendothelial system incomparison with
their uncoated counterparts [9]. It has been proved that PEG
corona could diminish non-speciﬁc interactions with serum
proteins and decrease the uptake of cationic polymer/DNA
complex by the macrophages in the liver and spleen leading
to an increased blood circulation time, which ultimately
improve the transfection efﬁciency of polycationic poly-
mers. Furthermore, the hydrophilicity of PLA nanoparticles
could be improved after modiﬁcation with PEG, and the
afﬁnity between polymers and DNA would be accordingly
enhanced which is favorable to load gene into the nanopar-
ticles. In addition, the microenvironment formed by PEG is
beneﬁcial to the activity of protein or gene agents in storage
or administration. In addition, although PEGylated PLA or
PLGA polymer have come out for a while as drug delivery
systems [10, 11], there are few reports on gene delivery
systems [12, 13]. Therefore the feasibility and suitability of
PEGylated PLA or PLGA polymer as gene delivery system
remains to be adequately investigated and addressed.
Usually plasmid DNA is encapsulated into PLGA/PLA
particles using the common water-in-oil-water (W/O/W)
double emulsion/solvent evaporation method in order to
achieve a better protection of plasmid and a more precise
control of the release process [14, 15]. However, the double
emulsion/solvent evaporation method can not guarantee the
integrity of DNA under ultra-sonication or high speed
homogenization, which is necessary in the encapsulation
process to obtain smaller particle size [16, 17]. One strat-
egy to solve the problem is to adsorb the plasmid DNA
onto the surface of cationic PLA/PLGA particles which are
modiﬁed to display a positively charged surface by inclu-
sion of cationic surfactants such as cetyltrimethyl ammo-
nium bromide (CTAB) in formulations [18, 19]. It was
reported that the cationic gene loaded particles substan-
tially improved the immune responses generated by DNA,
both in mouse and macaque models [20].
Based on these considerations, the main goal of the
present work was to develop a novel cationic PEGylated
PLA (PLA-PEG) nanoparticles and explore its applicability
and feasibility as a nonviral vector for gene transport. For
this purpose, cationic PLA-PEG nanoparticles with
appropriate positive charge and particle size was prepared
applying an easily performed nanoprecipitation technique
and using CTAB as a cationic surfactant and Tween 80 as a
cosurfactant. The cationic gene loaded PLA-PEG nano-
particles was then obtained by adsorbing plasmid DNA
onto the surface of cationic PLA-PEG nanoparticles
through electrostatic interactions. The physicochemical
properties and biological properties of the nanoparticles
were investigated and characterized, respectively.
Materials and Methods
Materials
Poly(ethylene glycol)-block-polylactide copolymer (PLA-
PEG, PEG average Mn 3,000 Da, PLA average Mn
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dong University). Cetyltrimethyl ammonium bromide
(CTAB) was purchased from Amresco (Amresco, China).
pEGFP-N1 was provided by Zhejiang University (China).
PicoGreen
 dsDNA reagent was obtained from Molecular
Probes (Invitrogen, USA). Agarose was purchased from
BIO-WEST (Spain). Goldview was obtained from Beijing
Saibaisheng Biological Engineering Co. (Beijing, China).
DNase I enzyme was obtained from Beijing Yinfeng
Century Scientiﬁc Develop Co., Ltd (Beijing, China). MTT
(3-[4, 5-dimehyl-2-thiazolyl]-2, 5-diphenyl-2H- tetrazo-
lium bromide) were purchased from Sigma-Aldrich
(China). Lipofectamine 2000 was from Invitrogen (USA).
Hela cell line was obtained from American Type Culture
Collection (ATCC, USA). All the other chemicals and
reagents used were of analytical purity grade or higher,
obtained commercially.
Preparation of Cationic PLA-PEG Nanoparticles
Cationic PLA-PEG nanoparticles (abbreviated as PLA-
PEG-NPs below) was prepared by the nanoprecipitation
method [21] according to the optimized formulation. Typi-
cally, accurately weighed (20 mg) PLA-PEG was dissolved
into 5 mL acetone under sonication. The resulting polymer
solution was slowly (30 mL/h) injected by a micro-syringe
pump (KDS 100, USA) into 20 mL magnetically stirring
(600 rpm, RCT basic stirrer, IKA, Germany) mixed sur-
factant solution containing CTAB (0.1%, w/v) and Tween
80(0.2%,w/v)andagitatedfor8 hatroomtemperatureuntil
complete evaporation of the organic solvent. The entire
dispersedsystemwasthencentrifuged(Beckman,Fullerton,
CA) at 15,000 rpm, 4 C for 30 min. The pellet was re-
suspended in Milli-Q water and washed three times to
remove the redundant surfactant. Finally it was re-sus-
pended in phosphate buffered saline (PBS, pH 7.4) solution
followed by ﬁltered through 0.45 lm nitrocellulose mem-
brane (Millipore) ﬁlter and was stored at 4 C until use.
Preparation and Optimization of Gene Loaded Cationic
PLA-PEG Nanoparticles
Adsorption of Plasmid DNA onto PLA-PEG-NPs
The gene loaded cationic PLA-PEG nanoparticles (abbre-
viated as DNA-PLA-PEG-NPs below) were obtained by
meansofelectrostaticattractionbetweentheanionicplasmid
DNAandtheblankcationicnanoparticles.Brieﬂy,thereport
gene pEGFP solution was added into PLA-PEG-NPs at a
ﬁxedweightratio(PLA-PEG:DNA,w/w).Themixedliquor
was kept for 20 min at room temperature and the resultant
DNA-PLA-PEG-NPs were directly used for further study.
Agarose Gel Electrophoresis of DNA/Nanoparticles
Complex
Complex formation between nanoparticles and DNA was
analyzed by agarose gel electrophoresis. The gels were
prepared with 0.8% (w/v) agarose in 20 mL TAE buffer
(40 mM Tris, 40 mM Acetic acid, 1 mM EDTA, pH 8.5)
containing 2 lL goldview as stains. A ﬁxed amount (1 lg)
of DNA was incubated with various amounts of PLA-PEG-
NPs in 100 lL of PBS (pH = 7.4) (the weight ratio of
PLA-PEG and DNA is 10:1, 50:1, 100:1, 150:1, 20:1,
500:1, respectively). The resultant DNA-PLA-PEG-NPs
and control plasmid DNA were applied to gel electropho-
resis at a constant 90 V for 25 min. After the electropho-
resis, images were obtained using UV transilluminator and
Multimage
TM Light Cabinet (Alpha Imagers EC, Alpha
Innotech Corporation) to show the location of DNA.
Determination of DNA Binding Efﬁciency
To measure the DNA binding efﬁciency of the DNA-PLA-
PEG-NPs, the free DNA was separated from the nanopar-
ticles by ultracentrifugation at 15000 rpm, 4 C for 30 min
and the free DNA in supernatants were collected and
analyzed using ﬂuorospectrophotometry with PicoGre-
enTM dsDNA quantitation reagent [22]. The ﬂuorescence
was measured by ﬂuorescence spectrophotometer (HIT-
ACHI 850, Japan) at excitation and emission wavelengths
of 480 and 520 nm, respectively. The amount of DNA was
calculated according to the linear calibration curve of DNA
(F = 2 9 10
-4 C ? 0.0437 R = 0.999 4). The binding
efﬁciency was calculated from the following equation:
DNAbindingefficiencyð%)
¼
ðtotalDNAcontent   freeDNAcontentÞ 100
totalDNAcontent
:
Morphology, Particle Size and Zeta Potential
of Nanoparticles
The morphology of PLA-PEG-NPs and DNA-PLA-PEG-
NPs was examined under transmission electron microscope
(TEM, JEM-1200EX, Japan). Samples were prepared by
placing a drop of nanoparticle suspension onto a copper grid
and air-dried, following negative staining with one drop of
2% aqueous solution of sodium phosphotungstate for con-
trast enhancement. The air-dried samples were then directly
examined under the transmission electronic microscope.
The average particle size, size distribution, and zeta
potential of the nanoparticles were measured by photon
correlation spectroscopy (PCS) using Zetasizer 3000
(Malvern Instruments, Malvern, England). All measure-
ments were carried out in triplicates. The average particle
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reported value was represented as mean ± SD (n = 3).
Stability Test of the DNA-PLA-PEG-NPs Against
DNase I
Protection of plasmid DNA from nucleases is one of the
most important properties for efﬁcient gene delivery both
in vitro and in vivo. To test whether DNA-PLA-PEG-NPs
can protect the loaded plasmid DNA from nucleases
digestion, the results of DNase I mediated digestion was
evaluated using agarose gel electrophoresis [23]. In brief,
100 lL of DNA-PLA-PEG-NPs containing 1 lg of DNA
were, respectively, incubated with different amounts of
DNase I (0.1, 0.2 and 0.4 U/lg DNA) in DNase I /Mg
2?
digestion buffer (50 mM, Tris–HCl, pH 7.6, and 10 mM
MgCl2). Naked DNA (1 lg) was treated with DNase I at
0.1 U/lg DNA as a reference. The suspension was incu-
bated in shaking water bath (100 rpm) for 30 min at 37 C.
After that, the enzymatic digestion reaction was terminated
with 5 lL EDTA solution (0.5 M, pH 8.0) for 10 min at
room temperature. To asses the integrity of DNA loaded in
the nanoparticles, it was dissociated from the cationic
nanoparticles by adding heparin solution [24], an anionic
glycosaminoglycan, at ﬁnal concentration of 1% (w/v) and
the suspension was then incubated in shaking water bath
(100 rpm) for 3 h at 37 C. The conﬁguration of plasmid
DNA in the nanoparticles after extraction was analyzed by
gel electrophoresis with untreated naked DNA as a refer-
ence. The samples were applied to a 0.8% (w/v) agarose
gel in TAE buffer as described above.
The Plasma Stability Investigation of DNA-PLA-PEG-
NPs
To examine resistance of DNA-PLA-PEG-NPs to DNA
degradation in plasma, 25 lL of plasmid DNA solution and
DNA-PLA-PEG-NPs were, respectively, incubated with
25 lL of 20% human plasma for 1 h in a 37 C incubator.
Immediately following the incubation, nucleases were
inactivated with 3 lL of EDTA solution (0.5 M, pH 8.0)
for 10 min at room temperature. Thereafter, the plasma
treated samples together with untreated DNA-PLA-PEG-
NPs and DNA were all applied to 0.8% (w/v) agarose gel
as described above.
The In Vitro Release of DNA-PLA-PEG-NPs
The Stability of Plasmid DNA in the Release Medium
During the prolonged in vitro drug release, the biomacro-
molecule drug may be degraded, and this may affect in
vitro drug release studies [13, 25]. Therefore, it is essential
to select a suitable drug release medium to protect the
plasmid DNA from degradation during in vitro drug release
period. Based on physiological environment and the result
of preliminary tests, the mixed solution containing phos-
phate buffered saline solution at pH 7.4 (100 mM) and
150 mM NaCl solution was selected as the release medium
for the DNA-PLA-PEG-NPs. The stability of plasmid DNA
in the release medium in the duration of in vitro release
was investigated at ﬁrst. Brieﬂy, 200 lL DNA solution
(10 lg/mL) were diluted with isovolumic release medium
mentioned above in Eppendorf
 tubes and then shaken
horizontally in water bath at 37 C and 100 rpm. Separate
tubes were used for each data point. At predetermined time
intervals (2 h, 5 h, 8 h, 12 h, 24 h, 2 days, 4 days, 7 days,
10 days, 15 days, 20 days), the samples were withdrawn
and the concentration of DNA was determined by the
PicoGreen ﬂuorimetric assay mentioned above. The
experiments were repeated three times and all measure-
ments were collected in triplicates. The proﬁle of percent
content of DNA versus time in release medium was drawn.
Measurement of In Vitro DNA Release
The proﬁles of in vitro DNA release from DNA-PLA-PEG-
NPs were measured over 20 days using separate samples
for each time point according to the following operations.
Typically, 200 lL of DNA-PLA-PEG-NPs (DNA concen-
tration: 10 lg/mL) were diluted with isovolumic release
medium in Eppendorf
 tubes and then shaken horizontally
in water bath at 37 C and 100 rpm. At predetermined time
intervals, the tubes were withdrawn and centrifugated at
15,000 rpm for 30 min, the supernatants were collected for
analysis. The amount of the released DNA was evaluated
by the PicoGreen ﬂuorimetric assay. Background readings
were corrected using the centrifugation supernatants from
blank nanoparticles.
Integrity Determination of Plasmid DNA After Release
The molecular form of DNA (often referred to as ‘‘topol-
ogy’’) has been demonstrated to affect the transfection efﬁ-
ciency in vitro and in vivo [26]. Supercoiled plasmid was
believedtobethemostefﬁcientformforcelltransfectionand
itwas establishedthattheorder oftransfectionefﬁciencywas
supercoiled[relaxed[linear [27]. Fabrication conditions
such as sonication, lyophilization, and change of pH were
reported previously to decrease the supercoiled content. It is
well known that the hydrolysis of PLA may substantially
decrease the pH in PLA nanoparticles, which potentially
change the topology structure of DNA and decrease the
biological activity of DNA accordingly. Therefore, it was
crucial to examine the plasmid structural and functional
integrity following release from nanoparticles.
Nanoscale Res Lett (2009) 4:982–992 985
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Structural integrity of plasmid DNA released from nanopar-
ticles at selective time points was evaluated by agarose gel
electrophoresis. To determine plasmid stability during
release, the samples released at several time points (i.e. 2 h,
8 h, 24 h, 4 days, 10 days, 15 days and 20 days) along with
controluntreatedplasmidDNAwereappliedto0.8%agarose
gel in TAE buffer. Band separation for topological structure
of plasmid DNA was observed after gel electrophoresis.
Functional Integrity Determination
The in vitro transfection experiment was performed to
investigate the functional integrity of released DNA. Hela
cells (ATCC) were seeded into 24-well plates at a density
of 1 9 10
5 cells/well 24 h prior to transfection and 1 lgo f
DNA of was used per well (n = 6 wells per formulation).
An aliquot of untreated DNA solution and supernatants of
nanoparticles in vitro release at different time points after
moderate concentration (1 day, 10 days, 20 days, equiva-
lent to 1 lg DNA) were complex with Lipofectamine 2000
according to the manufacturer’s instructions [28]. After
incubation for 4 h at 37 Ci n5 %C O 2 incubator, the ori-
ginal incubation media was replaced with 1 mL of com-
plete medium and cells were incubated sequentially until
24 h post transfection. The percentage of ﬂuorescent cells
(deﬁned as cells having ﬂuorescence levels above that of
untreated control cells) presented in every 10,000 cells
counted by the ﬂow cytometry was calculated. Transfection
experiments were performed in triplicates.
Cell Viability Test of DNA-PLA-PEG-NPs
The cytotoxicity of DNA-PLA-PEG-NPs was evaluated by
MTT method in Hela cell line [19]. Brieﬂy, the cells were
seeded into a 96-well microtiter plates at a density of
1 9 10
4 cells per well in 0.2 mL of RPMI 1640 culture
medium supplemented with 10% fetal bovine serum (FBS)
and antibiotics in 5% CO2 incubator at 37 C overnight.
After that, the culture medium was replaced by 200 lL
fresh serum-free RPMI 1640 medium with different con-
centrations of the nanoparticles (expressed as PLA-PEG
concentration, 5, 10, 25, 50, 100 and 250 lg/mL) and
Lipofectamine 2000 in comparison. The applied dosage of
gene vectors (Lipofectamine 2000/DNA complex and
DNA-PLA-PEG-NPs) were proportional to that used in
transfection experiment. After incubation for 24 h, 20 lL
of MTT stock solution in PBS (5 mg/mL, pH 7.4) was
added into each well at a ﬁnal concentration of 0.5 mg/mL
MTT. The plate was then incubated at 37 Ci n5 %C O 2 for
4 h. The medium was removed and 150 lL DMSO was
added to dissolve the formazan crystals. The plate was read
spectrophotometrically at 570 nm by microplate reader
(Model 680, BIO-RAD, USA). The cell viability (%) was
calculated and compared with the untreated control (100%)
according to the following equation:
Cellviabilityð%Þ¼ OD570ðsamplesÞ=OD570ðcontrolÞ

  100
OD570(samples) represented measurements from the cells
treated with samples and OD570(control) from the untreated
cells.
Statistical Analysis
All measurements were collected in triplicates and exper-
iments were repeated three times. Values were expressed as
mean ± standard deviation. Unpaired Student’s t-test was
used to assess statistical signiﬁcant differences (p\0.05)
between the group means.
In Vitro Transfection Assays of DNA-PLA-PEG-NPs
The transfection activity of DNA-PLA-PEG-NPs was
evaluated in Hela cell lines using plasmid DNA, encoding
enhanced green ﬂuorescence protein (EGFP) as reporter
gene in the transfection studies. The cells were seeded into
24-well plates at a density of about 1 9 10
5 cells per well
in 1 mL of RPMI 1640 culture medium with 10% FBS,
24 h prior to transfection. At a conﬂuence level of 70–80%,
cells were washed twice with PBS, and, respectively,
incubated with 500 lL of media (with or without 10%
FBS) containing 1 lg of DNA in transfection vectors at
37 C. Lipofectamine 2000 (Invitrogen) was used as
positive control, and the formulation of Lipofectamine/
DNA complex was carried out according to the manufac-
turer’s protocols. 1 lg of plasmid DNA was used as neg-
ative control. The cells were incubated with the vectors for
4 h, in the presence or absence of serum medium. The
transfection media was then replaced with 1 mL of fresh
complete culture media, and the cells were incubated
sequentially until 24 h post transfection. Detection of
expression of EGFP was carried out using an inverted
ﬂuorescent microscope with an attachment for ﬂuorescent
observation (OLYMPUS, ZX71, Japan) and the picture
was captured using a 4009 objective. Transfection exper-
iments were performed in triplicates.
Results and Discussions
Formation of PLA-PEG-NPs
In this study we have designed a novel cationic PLA-PEG
nanoparticles modiﬁed by CTAB as a nonviral vector for
986 Nanoscale Res Lett (2009) 4:982–992
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several good qualities, such as good biodegradability,
biocompatibility, and nonimmunogenicity, it takes on
negative surface charges because of the carboxylic end
groups of PLA. To prepare PLA-PEG mediated DNA
complex, the cationic surface-active agent CTAB was used
to modify the surface of PLA-PEG nanoparticles to make
the surface take on positive charges. However, it was found
that nanoparticles prepared with sole CTAB as surfactant
(CTAB-NPs) revealed highly aggregated structures and
heterogeneous size in TEM imaging (Fig. 1a), which was
in accord with the other report [29]. In contrast, nanopar-
ticles formulated with the popular non-ionic surfactant,
Tween 80 (Tween 80-NPs) exhibited a uniform and smaller
particle size without aggregation (Fig. 1b), which might be
due to the superior emulsifying capacity of Tween 80.
Moreover, it has some interesting characteristics useful for
gene therapy because of the presence of poly(ethylene-
glycol) (PEG) chains in its structure. It has been hypothe-
sized that Tween 80 may have a similar fusogenic property
with DOPE (Dioleylphosphatidylethanolamine) [30].
When a comparable concentration of Tween 80 is added to
the formulation of nanoparticles, their transfection capacity
will be improved signiﬁcantly [31]. Besides, Tween 80 has
another important characteristic for the transfection of
these systems in vivo. It creates a steric barrier [32] which
shields the excess of positive charges of the systems and
reduces the interaction with blood components, such as
serum proteins, which could limit the arrival of the gene
therapy system to the cell surface. Taking these into con-
sideration, Tween 80 was applied as a cosurfactant together
with the cationic surfactant CTAB to formulate PLA-PEG
nanoparticles in the present study.
Formation of DNA-PLA-PEG-NPs
Agarose gel electrophoresis and Picogreen-ﬂuorometry
method were, respectively, performed to investigate the
optimal ratio of NPs to DNA for the binding efﬁciency
qualitatively and quantitatively. It was observed that sole
plasmid DNA could migrate to the positive electrode under
the electric ﬁeld such as lane 1 and 8 in Fig. 2. Once DNA
was associated with the nanoparticles which was too large
to diffuse through the agarose matrix, the mobility of DNA
was hindered and it was detained in the well of the agarose
gel. In addition, the part of DNA which did not bind with
PLA-PEG-NPs migrated to the positive electrode in the
same manner with the control DNA. The results of agarose
gel electrophoresis (Fig. 2) showed that PLA-PEG-NPs
may bind with DNA to various degrees with different mass
ratios of NPs to DNA in the complex. There was
decreasing free DNA present in the lane with the increase
of the ratio of NPs/DNA. When the mass ratio of NPs to
DNA reached 100:1 or above, almost all DNA was com-
bined with NPs without free DNA bands in the lane visible.
Meanwhile, the results obtained by Picogreen-ﬂuorometry
analysis were consistent with that of agarose gel electro-
phoresis. As shown in Fig. 3, the binding efﬁciency was
increasingly raised with the mass ratio of NPs to DNA
from 10:1 to 100:1, and it was 95.36% when the ratio
reached 100:1. Further increase of the ratio did not sig-
niﬁcantly improve the binding efﬁciency but will decrease
the DNA loading efﬁciency of nanoparticles. Thus 100:1
was selected as the optimal mass ratio of NPs to DNA for
further study.
Fig 1 TEM imaging of CTAB-NPs (a) and Tween 80-NPs (b)
Fig. 2 Agarose gel electrophoresis analysis of PLA-PEG-NPs com-
bining with DNA at different mass ratio. Lane 1, 8: DNA Control;
Lane 2–7: the mass ratio of NPs/DNA was 10:1, 50:1, 100:1, 150:1,
200:1, 500:1, respectively
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and DNA-PLA-PEG-NPs
The transmission electron micrograph of PLA-PEG-NPs
and DNA-PLA-PEG-NPs was illustrated in Fig. 4. It was
shown that the obtained nanoparticles appeared similar
spherical in shape and separated from each other. Figure 5
showed a representative size distribution proﬁle of the
nanoparticles. The polydispersity index (PDI) of PLA-
PEG-NPs and DNA-PLA-PEG-NPs were 0.185 and 0.161,
respectively, demonstrating a relatively narrow particle
size distribution. The resultant PLA-PEG-NPs and DNA-
PLA-PEG-NPs were small in size with mean particle size
of 89.7 and 128.9 nm, respectively, and positive surface
charge with zeta potential of ?28.9 and ?16.8 mV,
respectively. It could be explained that while DNA com-
bined with PLA-PEG-NPs, the particles size increased and
the absolute value of surface charge decreased due to the
neutralization effect between the anionic DNA and the
cationic nanoparticles.
Protection of DNA-PLA-PEG-NPs Against DNase I
Degradation of DNA by nuclease, such as DNase I, is a
major barrier for gene delivery both in vitro and in vivo. To
test whether the resultant nanoparticles can protect loaded
plasmid DNA from nucleases digestion, the nanoparticles
were exposed to DNase I. Figure 6 showed that naked
plasmid DNA (lane 4) was completely digested by DNase I
at 0.1 U/lg DNA within 30 min of incubation, conﬁrming
the activity of nucleases. While DNA extracted from DNA-
PLA-PEG-NPs remained intact supercoiled form in the
investigated concentrations of DNase I within 30 min of
incubation (lane 2–4), similar to the DNA control in lane 5.
These results demonstrated that DNA-PLA-PEG-NPs
indeed could protect the loaded DNA from degradation by
DNase I at determinate concentrations for 30 min, and
maintained the structural integrity of gene.
Stability of DNA-PLA-PEG-NPs in Plasma
Figure 7 showed the stabilization of DNA-PLA-PEG-NPs
in plasma. It could be observed that the original plasmid
DNA bands in lane 1 disappeared at the exposure of 10%
human plasma for 1 h in lane 2, suggesting that the plasmid
DNA had been degraded completely by nucleases in
plasma. However, DNA-PLA-PEG-NPs remained rela-
tively stable in the presence of plasma, with most loaded
DNA detained in the well. This conﬁrmed that the DNA-
PLA-PEG-NPs could not only bind DNA efﬁciently onto
its surface but also partially protect the condensed DNA
against degradation by plasma protein, which was prom-
ising to improve the in vivo stability of DNA and favored
the in vivo delivery of theoretical gene.
In Vitro Release of DNA-PLA-PEG-NPs
The stability of plasmid DNA in the condition identical to
in vitro release of DNA-PLA-PEG-NPs was investigated
in the present study. As shown in Fig. 8, the DNA percent
content at the predetermined time point maintained above
95% during 20 days. It was clearly indicated that the
plasmid DNA could remain extremely stable in the
adoptive condition during the monitoring time without
substantial degradation, that was, the release medium has
potential to improve the stability of plasmid DNA and
prevent its degradation. This result could be explained that
dsDNA has higher stability at high salt concentrations and
physiological pH which was in agreement with other
report [33]. Therefore, the content of DNA released from
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Fig. 3 Binding efﬁciency of PLA-PEG-NPs with DNA at different
mass ratio (n = 3)
Fig. 4 TEM imaging of PLA-PEG-NPs (a) and DNA-PLA-PEG-NPs
(b)
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123DNA-PLA-PEG-NPs in vitro could be determined directly
and calculated without adjustment.
The in vitro drug release property is one of the important
characteristics of nanoparticles.
Figure 9 showed the accumulative release (expressed as
percentage of loaded DNA) versus time curve of DNA
from DNA-PLA-PEG-NPs in vitro during 20 days. Release
proﬁle of DNA from DNA-PLA-PEG-NPs exhibited an
initial burst of release of about 51.7% in the ﬁrst 12 h,
followed by slow and continuous release in 20 days. In
order to determine the release mechanism of DNA from
DNA-PLA-PEG-NPs, the release data were evaluated by
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Fig. 5 Representative size
distribution proﬁle for PLA-
PEG-NPs (a) and DNA-PLA-
PEG-NPs (b)
Fig. 6 Agarose gel electrophoresis of DNA-PLA-PEG-NPs after
being incubated with DNase I at different concentrations. Lane 1–3:
DNA-PLA-PEG-NPs incubated with different amount of DNase I at
0.1, 0.2, 0.4 U/lg DNA, respectively, for 30 min; Lane 4: Naked
DNA incubated with DNase I at 0.1 U/lg DNA for 30 min; Lane 5:
DNA control
Fig. 7 Plasma stability of DNA-PLA-PEG-NPs. 1: DNA control; 2:
Naked DNA incubated in 10% plasma for 1 h; 3: DNA-PLA-PEG-
NPs Control; 4: DNA-PLA-PEG-NPs incubated in 10% plasma for
1h
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Fig. 8 The proﬁle of content of DNA in release medium with time
(n = 3)
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123model-dependent methods, and the result showed that the
release behavior of DNA from DNA-PLA-PEG-NPs ﬁtted
into bioexponential ﬂow equation best: 100 - Q =
78.70e - 0.9919t ? 51.37e - 0.2073t (Ra = 0.998 2,
Rb = 0.993 6). It could be predicted that the established
DNA-PLA-PEG-NPs with a delayed release effect could
keep the loaded DNA prolonged action in vivo.
Integrity Investigation of the DNA Released
from DNA-PLA-PEG-NPs
Plasmid DNA released from DNA-PLA-PEG-NPs at vari-
ous time points was evaluated for its structural integrity on
0.8% agarose gel in comparison with control DNA
(Fig. 10). It can be observed that the DNA released from
DNA-PLA-PEG-NPs was predominantly supercoiled
(S.C.) in form and comparable with the native DNA.
Although some evidence of gradual increase in the per-
centage of open circular plasmid DNA (O.C.) was visible
at later time points, no linear conﬁguration was observed
during the process of in vitro release. These results indi-
cated that DNA-PLA-PEG-NPs could protect the loaded
plasmid DNA from degradation to some extent in the
release duration.
The results of the functional integrity of released DNA
based on in vitro transfection experiment were shown in
Table 1. It was evident from the result that DNA after
releasing from DNA-PLA-PEG-NPs still retained gene
expression activity. In the prophase of in vitro release
(1 day and 10 days), the released DNA from DNA-PLA-
PEG-NPs completely maintained its bioactivity as the in
vitro transfection efﬁciency of released DNA/lipofectamine
complex was equivalent to the untreated DNA that was
complexed with Lipofectamine 2000 (p[0.05). While in
the terminal in vitro release (20 days), the transfection
efﬁciency of the released DNA/Lipofectamine complex
was a little lower than the untreated DNA/Lipofectamine
complex (p\0.05). That results might be explained that
more DNA had converted into open circular with release
time as demonstrated by agarose gel electrophoresis
described above, and the bioactivity of open circular DNA
was reported to be less efﬁcient than supercoiled conﬁgu-
ration [34].
Evaluation of the Cytotoxicity of DNA-PLA-PEG-NPs
In vitro toxicity of DNA-PLA-PEG-NPs was evaluated by
MTT assay in Hela cells. The cytotoxicity of DNA-PLA-
PEG-NPs at various concentrations against Hela cell was
shown in Fig. 11. Lipofectamine 2000, which is commonly
used in in vitro gene transfection, was evaluated in com-
parison with DNA-PLA-PEG-NPs. As illustrated in
Fig. 11, the Hela cell viabilities decreased with the
increased concentration of DNA-PLA-PEG-NPs while
the average cell viabilities of different formulations at
the studied concentrations (5–250 lg/mL) were between
80 and 120% versus control cells and were all signiﬁcantly
higher than that of Lipofectamine 2000 (p\0.05), which
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Fig. 9 Accumulative release of DNA from DNA-PLA-PEG-NPs
(n = 3)
Fig. 10 Agarose gel electrophoresis of DNA released from DNA-
PLA-PEG-NPs
Table 1 Biological activity of
DNA released from DNA-PLA-
PEG-NPs (n = 3)
* p\0.05 compared with
untreated DNA/lipofectamine
complex
Untreated
DNA/lipofectamine
complex
Released DNA/lipofectamine complex
1 day 10 days 20 days
Transfection
efﬁciency (%)
51.01 ± 2.43 49.36 ± 2.83 46.95 ± 1.68 43.41 ± 2.36*
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123indicated that the DNA-PLA-PEG-NPs were much safer
than Lipofectamine 2000 to Hela cell.
In Vitro Transfection Studies
An efﬁcient gene delivery system is required to transport
the gene into cells and see to its eventual release, leading to
gene expression and subsequent protein synthesis. The
current study aimed to determine the ability of DNA-PLA-
PEG-NPs to transfer the reporter gene EGFP to Hela cell.
Transfection ability of our established vectors DNA-PLA-
PEG-NPs was investigated in comparison with the com-
mercial cationic liposome based reagent, Lipofectamine
2000 which was well known to provide high transfection
efﬁciency and high level of transgene expression in a range
of mammalian cell types in vitro. However, it was found
that cationic liposomes tended to bind with some serum
protein such as albumin in vivo, forming aggregation and
eliminated quickly, which led to relative lower transfection
efﬁciency. Thus it was meaningful to investigate the effects
of serum in transfection medium on the in vitro transfection
activity of gene vectors. In the present study, transfection
activities of them were compared in the system with or
without serum because serum was known to inﬂuence the
transfection efﬁciency of gene vectors sometimes [35]. The
results observed by inversion ﬂuorescence microscope after
transfection (Fig. 12) showed that DNA-PLA-PEG-NPs
may successfully transfer plasmid DNA into Hela cells,
and the gene can encode the green ﬂuorescent protein. It
was noticeable that DNA-PLA-PEG-NPs was a much more
efﬁcient carrier than the EGFP plasmid alone irrespective
of serum in the medium, which could barely transfect Hela
cell. In the absence of serum in the transfection medium,
DNA-PLA-PEG-NPs produced slightly lower transfection
efﬁciency than Lipofectamine 2000 during 24 h which
might be due to the sustained release property of DNA-
PLA-PEG-NPs. However, Lipofectamine 2000 showed
apparently diminished transfection activities in the pres-
ence of serum whereas DNA-PLA-PEG-NPs still main-
tained high transfection activity in the presence of serum,
which was visibly higher than that of Lipofectamine 2000.
These results indicated that the serum in the transfection
medium hardly inﬂuenced the transfection activity of
DNA-PLA-PEG-NPs but weakened the transfection activ-
ity of Lipofectamine 2000 signiﬁcantly. It might be
explained that cationic liposomes tended to adsorb anionic
serum protein and form a larger aggregate which could not
get across the cell membrane and deliver the DNA payload
to the nucleus. The DNA-PLA-PEG-NPs with PEGylation
could prevent the non-speciﬁc interactions with serum
protein and minimize particle aggregation in buffers
especially in the transfection medium and accordingly
improve the transfection efﬁciency of nanoparticles [36].
Conclusion
In the present work, cationic biodegradable nanoparticles
based on PEGylated PLA copolymers was formulated
using the mild and simple performed nanoprecipitation
technique. Report gene, pEGFP was adsorbed onto the
surface of the cationic PLA-PEG-NPs through electrostatic
interactions, leading to the gene loaded nanoparticles
(DNA-PLA-PEG-NPs). The obtained DNA-PLA-PEG-NPs
with high binding efﬁciency (95.36%), positive surface
charge (?16.8 mV) and small particle size (128.9 nm)
showed sustained-release of DNA in vitro within 20 days.
Adsorption and release from DNA-PLA-PEG-NPs did not
alter structural and functional integrity of plasmid DNA.
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Fig. 11 Cell viability of DNA-PLA-PEG-NPs against Hela cell line
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Fig. 12 Gene transfection of pEGFP in Hela cells (9400) (a, b) The
transfection results of DNA-PLA-PEG-NPs in absence and presence
of serum; (c, d): The transfection results of Lipofectamine 2000 in
absence and presence of serum; (e, f): The transfection results of
naked DNA in absence and presence of serum
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123Moreover, DNA adsorbed onto DNA-PLA-PEG-NPs was
efﬁciently protected from nuclease degradation and could
remain relatively stable in plasma. It was less toxic than
commercial Lipofectamine 2000 and safer to Hela cell.
And it could successfully transfer plasmid EGFP into Hela
cells, what’s more, the transfection activity was not
diminished dramatically by the serum in transfection
medium which surpassed the commercial cationic lipo-
some based reagent, Lipofectamine 2000. It could be
anticipated that the established DNA-PLA-PEG-NPs in
current study was a promising nonviral gene delivery
system used in gene therapy. It has a potential to alleviate
the acute toxicity effect of other vectors and prolong the
circulation time in vivo. Our further study will focus on the
optimization of the formulation for higher transfection
efﬁciency and the in vivo performance of the DNA-PLA-
PEG-NPs as gene delivery system will also be conducted.
Acknowledgments The Project was Sponsored by the Scientiﬁc
Research Foundation for the Returned Overseas Chinese Scholars,
State Education Ministry.
References
1. S.D. Li, L. Huang, J. Control Release 123, 181 (2007). doi:
10.1016/j.jconrel.2007.09.004
2. D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein, T. Kissel, Bio-
materials 24, 1121 (2003). doi:10.1016/S0142-9612(02)00445-3
3. O. Jeon, H.W. Lim, M. Lee, S.J. Song, B.S. Kim, J. Drug Target.
15, 190 (2007). doi:10.1080/10611860601143479
4. Y.M. Park, B.A. Shin, I.J. Oh, Arch. Pharm. Res. 31, 96 (2008).
doi:10.1007/s12272-008-1126-5
5. J.Panyam,V.Labhasetwar,Adv.DrugDeliv.Rev.55,329(2003).
doi:10.1016/S0169-409X(02)00228-4
6. J. Panyam, W.H. Zhou, S. Prabhaa, S.K. Sahoo, V. Labhaskar,
FASEB J. 16, 1217 (2002). doi:10.1096/fj.02-0088com
7. J. Luten, C.F. Van Nostrum, S.C. De Smedt, W.E. Hennink, J.
Control Release 126, 97 (2008). doi:10.1016/j.jconrel.2007.
10.028
8. P.C. Ross, S.W. Hui, Biochim. Biophys. Acta. 1421, 273 (1999).
doi:10.1016/S0005-2736(99)00132-7
9. T. Riley, T. Govender, S. Stolnik, C.D. Xiong, M.C. Garnett, L.
Illum, S.S. Davis, Colloids Surf. B Biointerfaces 16, 147 (1999).
doi:10.1016/S0927-7765(99)00066-1
10. X. Gao, W. Tao, W. Lu, Q. Zhang, Y. Zhang, X. Jiang, S. Fu,
Biomaterials 27, 3482 (2006). doi:10.1016/j.biomaterials.2006.
01.038
11. M. Pulkkinen, J. Pikkarainen, T. Wirth, T. Tarvainen, V. Haapa-
aho, H. Korhonen, J. Seppa ¨la ¨,K .J a ¨rvinen, Eur. J. Pharm. Bi-
opharm. 70, 66 (2008). doi:10.1016/j.ejpb.2008.04.018
12. J. Chen, B. Tian, X. Yin, Y. Zhang, D. Hu, Z. Hu, M. Liu, Y. Pan,
J. Zhao, H. Li, C. Hou, J. Wang, Y. Zhang, J. Biotechnol. 130,
107 (2007). doi:10.1016/j.jbiotec.2007.02.007
13. C. Perez, A. Sanchez, D. Putnam, D. Ting, R. Langer, M.J.
Alonso, J. Control Release 75, 211 (2001). doi:10.1016/S0168-
3659(01)00397-2
14. S. Prabha, V. Labhasetwar, Pharm. Res. 21, 354 (2004). doi:
10.1023/B:PHAM.0000016250.56402.99
15. N. Rizkalla, C. Range, F.X. Lacasse, P. Hildgen, J. Microen-
capsul. 23, 39 (2006). doi:10.1080/02652040500286185
16. H. Mok, T.G. Park, Eur. J. Pharm. Biopharm. 68, 105 (2008). doi:
10.1016/j.ejpb.2007.04.022
17. R.K. Evans, Z. Xu, K.E. Bohannon, B. Wang, M.W. Bruner, D.B.
Volkin, J. Pharm. Sci. 89, 76 (2000). doi:10.1002/(SICI)1520-
6017(200001)89:1\76::AID-JPS8[3.0.CO;2-U
18. M. Singh, J.H. Fang, J. Kazzaz, M. Ugozzoli, J. Chesko, P.
Malyala, R. Dhaliwal, R. Wei, M. Hora, D. O’Hagan, Int. J.
Pharm. 327, 1 (2006). doi:10.1016/j.ijpharm.2006.07.033
19. A. Basarkar, D. Devineni, R. Palaniappan, J. Singh, Int. J. Pharm.
343, 247 (2007). doi:10.1016/j.ijpharm.2007.05.023
20. M. Singh, M. Briones, G. Ott, D. O’Hagan, Proc. Natl. Acad. Sci.
USA 97, 811 (2000). doi:10.1073/pnas.97.2.811
21. W. Zou, C. Liu, Z. Chen, N. Zhang, Int. J. Pharm. 370, 187
(2009). doi:10.1016/j.ijpharm.2008.11.016
22. S.P. Barman, L. Lunsford, P. Chambers, M.L. Hedley, J. Control
Release 69, 337 (2000). doi:10.1016/S0168-3659(00)00308-4
23. C.G. Oster, M. Wittmar, U. Bakowsky, T. Kissel, J. Control
Release 111, 371 (2006). doi:10.1016/j.jconrel.2005.12.004
24. A. Agarwal, R. Vilensky, A. Stockdale, Y. Talmon, R.C. Unfer,
S.K. Mallapragada, J. Control Release 121, 28 (2007). doi:
10.1016/j.jconrel.2007.05.008
25. U. Bilati, E. Alle ´mann, E. Doelker, Eur. J. Pharm. Biopharm. 59,
375 (2005). doi:10.1016/j.ejpb.2004.10.006
26. K. Remaut, N.N. Sanders, F. Fayazpour, J. Demeester, S.C. De
Smedt, J. Control Release 115, 335 (2006). doi:10.1016/j.jconrel.
2006.08.009
27. H. Weintraub, P.F. Cheng, K. Conrad, Cell 46, 115 (1986). doi:
10.1016/0092-8674(86)90865-2
28. M. Dunne, D.C. Bibby, J.C. Jones, S. Cudmore, J. Control
Release 92, 209 (2003). doi:10.1016/S0168-3659(03)00304-3
29. C.G. Oster, N. Kim, L. Grode, L. Barbu-Tudoran, A.K. Schaper,
S.H. Kaufmann, T. Kissel, J. Control Release 104, 359 (2005)
30. F. Liu, J. Yang, L. Huang, D. Liu, Pharm. Res. 13, 1642 (1996).
doi:10.1023/A:1016480421204
31. S.H. Choi, S.E. Jin, M.K. Lee, S.J. Lim, J.S. Park, B.G. Kim,
W.S. Ahn, C.K. Kim, Eur. J. Pharm. Biopharm. 68, 545 (2008).
doi:10.1016/j.ejpb.2007.07.011
32. P. Harvie, F.M. Wong, M.B. Bally, J. Pharm. Sci. 89, 652 (2006).
doi:10.1002/(SICI)1520-6017(200005)89:5\652::AID-JPS11[3.
0.CO;2-H
33. E. Walter, K. Moelling, J. Pavlovic, H.P. Merkle, J. Control
Release 61, 361 (1999). doi:10.1016/S0168-3659(99)00151-0
34. A.P. Rolland, R.J. Mumper, Adv. Drug Deliv. Rev. 30, 151
(1998). doi:10.1016/S0169-409X(97)00101-4
35. A. Swami, A. Aggarwal, A. Pathak, S. Patnaik, P. Kumar, Y.
Singh, K.C. Gupta, Int. J. Pharm. 335, 180 (2007). doi:10.1016/
j.ijpharm.2006.11.033
36. C. Olbrich, U. Bakowsky, C.M. Lehr, R.H. Mu ¨ller, C. Kneuer, J.
Control Release 77, 345 (2001). doi:10.1016/S0168-3659(01)
00506-5
992 Nanoscale Res Lett (2009) 4:982–992
123